Autonomix Medical

Autonomix is focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. Nasdaq: $AMIX

[Autonomix Medical @AutonomixMed]

In a new CEO Corner segment, CEO Brad Hauser highlights the Company’s growing scientific and clinical recognition as its differentiated nerve-sensing and transvascular denervation platform gains traction across leading global medical conferences. https://t.co/5cHjQHssaq $AMIX

[Autonomix Medical @AutonomixMed]

Autonomix today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. Watch here: https://t.co/5cHjQHssaq $AMIX

[Autonomix Medical @AutonomixMed]

In the latest Virtual Investor “What This Means”, Dr. Toufic Kachaamy discusses the significance of Autonomix’s Society of Surgical Oncology podium presentation and the clinical relevance of the data in a new Virtual Investor “What This Means.” https://t.co/SPrsQvdeGF $AMIX

[Virtual Investor Co. @InvestorVirtual]

Dr. Toufic Kachaamy, Chief of Medicine at City of Hope Phoenix, joins a #WhatThisMeans segment to discuss the clinical significance of $AMIX’s data presented at the SSO Annual Meeting and its selection for a podium presentation.

🔗: https://t.co/Pqr6PuEUpL
#MedTech

[Autonomix Medical @AutonomixMed]

In a new Virtual Investor “What This Means” segment, Dr. Toufic Kachaamy discusses Autonomix’s differentiated approach to visceral cancer pain, pancreatic cancer feasibility data, and broader potential of its peripheral nervous system platform. Watch: https://t.co/coRcpZydZ7 $AMIX

[Autonomix Medical @AutonomixMed]

Brad Hauser, Chief Executive Officer of Autonomix Medical, comments on the issuance of a new U.S. patent that further strengthens the Company’s intellectual property foundation for next-generation neuromodulation technologies: https://t.co/S0jUOSjo0i $AMIX

[Autonomix Medical @AutonomixMed]

Autonomix's recently issued patent provides IP protection for technology that unlocks minimally invasive transvascular access to nerve targets and tissues through and beyond the lumen wall. Read more about Autonomix's growing global IP portfolio: https://t.co/S0jUOSjo0i $AMIX

[Autonomix Medical @AutonomixMed]

Autonomix today announced the @USPTO has issued U.S. Patent No. 12,544,131 (the “131 patent”), titled “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall.” Read more: https://t.co/S0jUOSjo0i $AMIX

[Autonomix Medical @AutonomixMed]

“These abstract acceptances at #EuroPCR underscore the expanding interest in precision-guided, transvascular approaches to peripheral nerve targeting,” said Brad Hauser, Chief Executive Officer of Autonomix. Read more: https://t.co/DS3fNxvtVA $AMIX

[Autonomix Medical @AutonomixMed]

Autonomix announced two abstracts highlighting our innovative transvascular nerve-targeting platform technology have been accepted for presentation at #EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, May 19–22, 2026. https://t.co/DS3fNxvtVA $AMIX

[Autonomix Medical @AutonomixMed]

Every major breakthrough starts with a question no one had answer yet. This #NationalCancerResearchMonth, we're focused on one of oncology's hardest problems: managing pain in pancreatic cancer patients. $AMIX is building technology to map & target specific nerves driving pain.

[Autonomix Medical @AutonomixMed]

This week at #DDW2026 in Chicago, we're sharing long-term data highlighting outcomes from our transvascular RF ablation proof-of-concept study designed to disrupt nerve signaling pathways associated with pain.

📍 Chicago
📅 May 2-5, 2026

$AMIX #DDW2026

[Autonomix Medical @AutonomixMed]

“This acceptance at #DDW2026 underscores our strategy of socializing and validating our data at preeminent conferences alongside world-renowned KOLs and clinical leaders,” said Dr. Robert Schwartz, Autonomix Co-Founder and CMO. More on the presentation: https://t.co/hmRLWJq07D $AMIX

[Autonomix Medical @AutonomixMed]

Sense. Treat. Verify. Our mission is to transform patient outcomes by advancing our propriety precision guided technology.

$AMIX #PainManagement #PancreaticCancer

[Autonomix Medical @AutonomixMed]

Autonomix's long-term data, "Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation”, has been accepted for presentation at #DDW2026, held May 2–5, 2026, in Chicago, IL and virtually. https://t.co/hmRLWJq07D $AMIX

[Autonomix Medical @AutonomixMed]

Autonomix is heading to ECIO 2026 April 26–30 in Basel, Switzerland.

We look forward to joining experts in interventional oncology to exchange ideas and advance innovation in patient care.

$AMIX #PainManagement #PancreaticCancer

[Autonomix Medical @AutonomixMed]

Autonomix's upcoming presentation at @ECIOcongress 2026 on Wednesday, April 29th will highlight long-term outcomes from the Company’s ongoing clinical evaluation of its minimally invasive, transvascular RF energy-based approach. Details: https://t.co/4cSPSpHori #ECIO2026 $AMIX

[Autonomix Medical @AutonomixMed]

Autonomix today announced that new long-term clinical data evaluating its transvascular RF ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at @ECIOcongress 2026 being held April 26-30, 2026 in Basel, CH. https://t.co/4cSPSpHori #ECIO2026 $AMIX

[Autonomix Medical @AutonomixMed]

“Being selected for a Featured Abstract presentation at SIR underscores the importance of advancing novel approaches to address cancer-related pain,” said Brad Hauser, Autonomix CEO. Read more about our upcoming podium presentation at #SIR26TOR: https://t.co/gTk9JXnb85 $AMIX

[Autonomix Medical @AutonomixMed]

Autonomix's abstract being presented as a Featured Abstract for podium presentation at the upcoming @SIRspecialists 2026 Annual Scientific Meeting is among a select group recognized for its scientific merit and clinical significance. Read more: https://t.co/HMcTllkYao #SIR26TOR $AMIX